COZAAR TABLET 50 mg

País: Singapur

Idioma: anglès

Font: HSA (Health Sciences Authority)

ingredients actius:

LOSARTAN POTASSIUM

Disponible des:

ORGANON SINGAPORE PTE. LTD.

Codi ATC:

C09CA01

Dosis:

50 mg

formulario farmacéutico:

TABLET, FILM COATED

Composición:

LOSARTAN POTASSIUM 50 mg

Vía de administración:

ORAL

tipo de receta:

Prescription Only

Fabricat per:

Organon Pharma (UK) Limited

Estat d'Autorització:

ACTIVE

Data d'autorització:

1996-03-08

Informació per a l'usuari

Page 1 of 9 
PRODUCT CIRCULAR 
SG-MK0954-T-092013 

Tablets 
COZAAR
® 
(losartan potassium) 
USE IN PREGNANCY 
Drugs that act directly on the renin-angiotensin system can cause
injury and death to the developing fetus. 
When pregnancy is detected, discontinue COZAAR as soon
as possible. 

I.  THERAPEUTIC CLASS 

COZAAR*
[/sg_wm_2107.html#1] (losartan potassium), the first of a new class of antihypertensives, is an angiotensin II receptor (type 
AT1)  antagonist. COZAAR also provides a reduction in the
risk of stroke  in hypertensive patients with left 
ventricular hypertrophy and renal protection for type 2
diabetic patients with proteinuria.   

II.  INDICATIONS 

Hypertension 
COZAAR is indicated for the treatment of hypertension. 

Hypertensive Patients with Left Ventricular Hypertrophy 
COZAAR is indicated for  the  reduction in the risk of stroke in hypertensive patients with left ventricular 
hypertrophy (see RACE). 

Renal Protection in Type 2 Diabetic Patients with Proteinuria 
COZAAR is indicated to delay the progression of renal disease
as measured by a reduction in the incidence of 
doubling of serum creatinine and end stage renal disease (need for dialysis or renal transplantation), and to 
reduce proteinuria. 

III.  DOSAGE AND ADMINISTRATION 

COZAAR may be administered with or without food.

COZAAR may be administered with other antihypertensive agents. 

*
 Registered Trademark of E.I. duPONT de Nemours and
Company, Wilmington, Delaware, USA 
  Copyright © 2010, 2011 Merck Sharp & Dohme Corp., a
subsidiary of Merck & Co., Inc., Whitehouse Station, 
NJ, USA. All Rights Reserved. 

COZAAR 
SG-MK0954-T-092013 

(losartan potassium) 

Page 2 of 9 
Hypertension

The usual starting and maintenance do

Fitxa tècnica

PRODUCT CIRCULAR
SG-OG0954-T-102021
Tablets
COZAAR®
(losartan potassium)
USE IN PREGNANCY
Drugs that act directly on the renin-angiotensin system can cause
injury and death to the developing
fetus. When pregnancy is detected, discontinue COZAAR as soon as
possible.
I. THERAPEUTIC CLASS
COZAAR (losartan potassium), the first of a new class of
antihypertensives, is an angiotensin II receptor (type
AT
1
) antagonist. COZAAR also provides a reduction in the risk of stroke
in hypertensive patients with left
ventricular hypertrophy and renal protection for type 2 diabetic
patients with proteinuria.
II. INDICATIONS
Hypertension
COZAAR is indicated for the treatment of hypertension.
Hypertensive Patients with Left Ventricular Hypertrophy
COZAAR is indicated for the reduction in the risk of stroke in
hypertensive patients with left ventricular
hypertrophy (see RACE).
Renal Protection in Type 2 Diabetic Patients with Proteinuria
COZAAR is indicated to delay the progression of renal disease as
measured by a reduction in the incidence
of doubling of serum creatinine and end stage renal disease (need for
dialysis or renal transplantation), and
to reduce proteinuria.
III. DOSAGE AND ADMINISTRATION
COZAAR may be administered with or without food.
COZAAR may be administered with other antihypertensive agents.
Hypertension
The usual starting and maintenance dose is 50 mg once daily for most
patients. The maximal antihypertensive
effect is attained 3-6 weeks after initiation of therapy. Some
patients may receive an additional benefit by
increasing the dose to 100 mg once daily.
For patients with intravascular volume-depletion (e.g., those treated
with high-dose diuretics), a starting dose
of 25 mg once daily should be considered (see PRECAUTIONS).
No initial dosage adjustment is necessary for elderly patients up to
75 years of age, or for patients with mild
renal impairment. For patients above 75 years of age, patients with
moderate to severe renal impairment and
patients on dialysis, a lower starting dose of 25 mg is recommended